Mammoth Biosciences
Peng Wang is a Senior Scientist I at Mammoth Biosciences since June 2023, previously serving as a Scientist II at Sorrento Therapeutics, Inc. from September 2020 to May 2023, where responsibilities included the design, synthesis, and characterization of novel lipid libraries for LNP formulation and mAb/Fab bioconjugation for targeted delivery of mRNA/pDNA LNP. Prior experience includes a role as a Postdoctoral Researcher at The Scripps Research Institute from May 2018 to September 2020, and as a Research and Teaching Assistant at Michigan State University from July 2011 to April 2018. Peng Wang holds a Ph.D. in Organic Chemistry from Michigan State University (2011-2018) and a Bachelor's Degree in Chemistry from Peking University (2007-2011).
Mammoth Biosciences
3 followers
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.